Óscar  Llorca

Óscar Llorca

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1999 in Nature
Verified
Journal Article
Closed access
ÓLÓscar Llorca
Óscar Llorca
EMElizabeth A. McCormack
Elizabeth A. McCormack
GHGillian Hynes
Gillian Hynes
JGJulie Grantham
Julie Grantham
JCJacqueline Cordell
Jacqueline Cordell
José M. ValpuestaJosé M. Valpuesta
José M. Valpuesta

1 May 2006 in Molecular Cell
Verified
Journal Article
Closed access
LSLaura Spagnolo
Laura Spagnolo
ARAngel Rivera-Calzada
Angel Rivera-Calzada
LPLaurence H. Pearl
Laurence H. Pearl
ÓLÓscar Llorca
Óscar Llorca

1 October 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RMRubén Martínez-Barricarte
Rubén Martínez-Barricarte
MHMeike Heurich
Meike Heurich
FVFrancisco Valdes-Cañedo
Francisco Valdes-Cañedo
EVEduardo Vazquez-Martul
Eduardo Vazquez-Martul
ETEva Torreira
Eva Torreira
SCSantiago Rodríguez De Córdoba
Santiago Rodríguez De Córdoba
Dense deposit disease (DDD) is a severe renal disease characterized by accumulation of electron-dense material in the mesangium and glomerular basement membrane. Previously, DDD has been associated with deficiency of factor H (fH), a plasma regulator of the alternative pathway (AP) of complement activation, and studies in animal models have linked pathogenesis to the massive complement factor 3 (C3) activation caused by this deficiency. Here, we identified a unique DDD pedigree that associates disease with a mutation in the C3 gene. Mutant C3923ΔDG, which lacks 2 amino acids, could not be cleaved to C3b by the AP C3-convertase and was therefore the predominant circulating C3 protein in the patients. However, upon activation to C3b by proteases, or to C3(H2O) by spontaneous thioester hydrolysis, C3923ΔDG generated an active AP C3-convertase that was regulated normally by decay accelerating factor (DAF) but was resistant to decay by fH. Moreover, activated C3b923ΔDG and C3(H2O)923ΔDG were resistant to proteolysis by factor I (fI) in the presence of fH, but were efficiently inactivated in the presence of membrane cofactor protein (MCP). These characteristics cause a fluid phase–restricted AP dysregulation in the patients that continuously activated and consumed C3 produced by the normal C3 allele. These findings expose structural requirements in C3 that are critical for recognition of the substrate C3 by the AP C3-convertase and for the regulatory activities of fH, DAF, and MCP, all of which have implications for therapeutic developments.

1 July 2008 in Molecular Cell
Verified
Journal Article
Closed access
JSJonathan P. Schuermann
Jonathan P. Schuermann
JJJianwen Jiang
Jianwen Jiang
JCJorge Cuéllar
Jorge Cuéllar
ÓLÓscar Llorca
Óscar Llorca
LWLiping Wang
Liping Wang
RSrui sousa
rui sousa

15 November 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
ÓLÓscar Llorca
Óscar Llorca
JMJaime Martín-Benito
Jaime Martín-Benito
MRMonica Ritco‐Vonsovici
Monica Ritco‐Vonsovici
JGJulie Grantham
Julie Grantham
GHGillian M. Hynes
Gillian M. Hynes
José M. ValpuestaJosé M. Valpuesta
José M. Valpuesta
Three‐dimensional reconstruction from cryoelectron micrographs of the eukaryotic cytosolic chaperonin CCT complexed to tubulin shows that CCT interacts with tubulin (both the α and β isoforms) using five specific CCT subunits. The CCT–tubulin interaction has a different geometry to the CCT–actin interaction, and a mixture of shared and unique CCT subunits is used in binding the two substrates. Docking of the atomic structures of both actin and tubulin to their CCT‐bound conformation suggests a common mode of chaperonin–substrate interaction. CCT stabilizes quasi‐native structures in both proteins that are open through their domain‐connecting hinge regions, suggesting a novel mechanism and function of CCT in assisted protein folding.

24 May 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ATAgustín Tortajada
Agustín Tortajada
HYHugo Yébenes
Hugo Yébenes
CACynthia Abarrategui-Garrido
Cynthia Abarrategui-Garrido
JAJaouad Anter
Jaouad Anter
JGJesús M. García-Fernández
Jesús M. García-Fernández
SCSantiago Rodríguez De Córdoba
Santiago Rodríguez De Córdoba
C3 glomerulopathies (C3G) are a group of severe renal diseases with distinct patterns of glomerular inflammation and C3 deposition caused by complement dysregulation. Here we report the identification of a familial C3G-associated genomic mutation in the gene complement factor H–related 1 (CFHR1), which encodes FHR1. The mutation resulted in the duplication of the N-terminal short consensus repeats (SCRs) that are conserved in FHR2 and FHR5. We determined that native FHR1, FHR2, and FHR5 circulate in plasma as homo- and hetero-oligomeric complexes, the formation of which is likely mediated by the conserved N-terminal domain. In mutant FHR1, duplication of the N-terminal domain resulted in the formation of unusually large multimeric FHR complexes that exhibited increased avidity for the FHR1 ligands C3b, iC3b, and C3dg and enhanced competition with complement factor H (FH) in surface plasmon resonance (SPR) studies and hemolytic assays. These data revealed that FHR1, FHR2, and FHR5 organize a combinatorial repertoire of oligomeric complexes and demonstrated that changes in FHR oligomerization influence the regulation of complement activation. In summary, our identification and characterization of a unique CFHR1 mutation provides insights into the biology of the FHRs and contributes to our understanding of the pathogenic mechanisms underlying C3G.